| Name | Title | Contact Details |
|---|---|---|
Kelly Brown |
Interim Associate Dean and Chief Information Officer | Profile |
Uduak Ndoh |
Chief Information Officer and Associate Dean for Information Technology | Profile |
Wellnet Healthcare is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Mental Health Association of South Central Kansas (MHASCK) has been serving the Sedgwick County Community since 1957. We are a 501(c)3 non-profit organization, a United Way agency and an affiliate of Sedgwick County COMCARE. We believe these
Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada`s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada`s largest database of medical cannabis patients. The company`s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.
Get in shape, build strength, tone, and lose weight, faster with BurnAlong.
We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our efforts are currently focused on the fields of neurology, nephrology and rheumatology, areas of medicine which have significant unmet medical needs. Our main product is H.P Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones used in a variety of disorders having an inflammatory component. We are currently supporting research in a number of rare conditions, where there is significant unmet need for treatment alternatives to standard therapies. We are also actively supporting research efforts to better understand disease processes and therapeutic mechanisms of action in conditions where Acthar might potentially play a role in treatment.